Author(s):
Thamarai Selvan Dhandapani, Raagul Seenivasan, Vijayaraghavan Krishnan, Vivekanandan Elango, Sakthi Shanmuga Jeyandar Lakshmanan, Balagee Muthukumar, Dhandapani Nagasamy Venkatesh
Email(s):
nagasamyvenkatesh@jssuni.edu.in
DOI:
10.52711/0974-360X.2026.00001 
Address:
Thamarai Selvan Dhandapani1, Raagul Seenivasan1, Vijayaraghavan Krishnan1, Vivekanandan Elango1, Sakthi Shanmuga Jeyandar Lakshmanan1, Balagee Muthukumar2, Dhandapani Nagasamy Venkatesh1*
1Department of Pharmaceutics, JSS College of Pharmacy
(JSS Academy of Higher Education and Research, Mysuru), Ooty – 643001, Nilgiris, Tamil Nadu, India.
2Department of Pharmaceutical Analysis, JSS College of Pharmacy
(JSS Academy of Higher Education and Research, Mysuru), Ooty – 643001, Nilgiris, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 1,
Year - 2026
ABSTRACT:
Similar to other antiretroviral medications, atazanavir, is a protease inhibitor (PI) that is used to treat human immunodeficiency virus (HIV) infection. This work aimed to adopt a solid dispersion approach with ß-cyclodextrin as the carrier to increase the atazanavir sulfate's water solubility. Different batches of atazanavir sulfate solid dispersions and physical mixes were produced, and the effects of carrier type and concentration on the solubility and dissolution of atazanavir sulfate were systematically examined. Various analytical techniques such as Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), X-ray diffraction (XRD), and Scanning Electron Microscopy (SEM), were utilized to study the compatibility between the carrier and drug, and the degree of crystallinity and surface morphology of the solid dispersion to assess the increase in the solubility and dissolution rate. Studies on compatibility using FTIR and DSC revealed that there was no interaction between drug with carrier. The batch formulated employing a 1:5 ratio of drug to polymer by kneading method showed good in vitro dissolution properties over the other batches and pure drug. The drug release from the formulation was found to obey first-order kinetics and diffusion as their main mechanism of release.
Cite this article:
Thamarai Selvan Dhandapani, Raagul Seenivasan, Vijayaraghavan Krishnan, Vivekanandan Elango, Sakthi Shanmuga Jeyandar Lakshmanan, Balagee Muthukumar, Dhandapani Nagasamy Venkatesh. Solubility Enhancement of Atazanavir Sulfate by Inclusion Complexation with β-cyclodextrin using Solid Dispersion Technique. Research Journal of Pharmacy and Technology. 2026;19(1):1-6. doi: 10.52711/0974-360X.2026.00001
Cite(Electronic):
Thamarai Selvan Dhandapani, Raagul Seenivasan, Vijayaraghavan Krishnan, Vivekanandan Elango, Sakthi Shanmuga Jeyandar Lakshmanan, Balagee Muthukumar, Dhandapani Nagasamy Venkatesh. Solubility Enhancement of Atazanavir Sulfate by Inclusion Complexation with β-cyclodextrin using Solid Dispersion Technique. Research Journal of Pharmacy and Technology. 2026;19(1):1-6. doi: 10.52711/0974-360X.2026.00001 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-1-1
REFERENCES:
1. Robin Wood. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008; 6(6): 785–796 doi:10.1586/14787210.6.6.785.
2. Schwarcz SK, Hsu LC, Vittinghoff E, Katz MH. Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987–1996. Am J Epidemiol. 2000; 152(2): 178–185.
3. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997; 337(11): 734–739.
4. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1 EuroSIDA Study Group. Lancet. 1998; 352(9142): 1725–1730.
5. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13): 853–860.
6. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon, D, Richman D, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. N Engl J Med. 1997; 337(11): 734-739 doi: 10.1056/NEJM199709113371102.
7. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nature Med. 2003; 9: 867-873 doi. 10.1038/nm0703-867.
8. Singh G, Pai RS. Atazanavir loaded Eudragit RL 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal. Drug Delivery, 2014; 23(2): 532-539 doi: 10.3109/10717544.2014.930760.
9. Mundada AS. Solid Dispersion: A Review. International Journal of Pharmacy Research & Technology, 2021; 11(2): 1-14 https://doi.org/10.31838/ijprt/11.02.01
10. 9.Jashna K Kani, Elizabeth N Xavier. Solubility enhancement of embelin by complexation with β-cyclodextrin. 2021; 55(2): 405-413. doi:10.5530/ijper.55.2s.112
11. Corrigan OI, Murphy CA, Timoney RP. Dissolution properties of polyethylene glycols and polyethylene glycol-drug systems. Int J Pharm. 1979; 4(1): 67-74.
12. Yong JI, Jeong CO. Dissolution enhancement of metoclopramide by coprecipitation with water-soluble carriers. J. Pharm. Investig. 1988; 18(2): 43-47.
13. Ganesh Chaulang, Kundan Patil, Dhananjay Ghodke, Shagufta Khan, Pramod Yeole. Research J. Pharm. and Tech. 2008;1(4): 386-389.
14. Nidhi Mishra, Shikha Srivastava. Characterization and solubility enhancement of etoricoxib in solid dispersion systems using lipid carriers Gelucire 44/14. Research J. Pharm. and Tech. 2010; 3(2): 578-582.
15. Atefe Rezaei, Ali Nasirpour. Evaluation of release kinetics and mechanisms of curcumin and curcumin-β-cyclodextrin inclusion complex incorporated in electrospun almond gum/PVA nanofibers in simulated saliva and simulated gastrointestinal conditions. Bio Nano Science. 2019; 9:438–445 doi:10.1007/s12668-019-00620-4
16. Khan, KA. The concept of dissolution efficiency. The Journal of Pharmacy and Pharmacology. 1975; 27(1): 48-49.